Fennec CSO acquires 155 shares via vesting

Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired additional common shares through a derivative exercise/conversion.

Rhea-AI Filing Summary

Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired additional common shares through a derivative exercise/conversion. On April 30, 2026, 155 common shares were released from restriction from shares awarded on March 28, 2025, increasing her directly held stake.

Following this release, Cioffi directly owns 24,020 common shares. The transaction reflects routine equity-based compensation vesting rather than an open-market purchase, as the reported price per share was $0.0000.

Insider Trade Summary

Exercise: 155 shares

Exercise 1 txn

Insider Cioffi Christiana Marie

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Exercise	Common shares	155	$0.00	$0.00

Holdings After Transaction: Common shares — 24,020 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Shares acquired: 155 common shares Post-transaction holdings: 24,020 common shares Reported transaction price: $0.0000 per share +2 more

5 metrics

Shares acquired 155 common shares Released from restriction on April 30, 2026

Post-transaction holdings 24,020 common shares Direct ownership after April 30, 2026 transaction

Reported transaction price $0.0000 per share Form 4 non-derivative transaction entry

Transaction date April 30, 2026 Date of derivative exercise/conversion

Award grant date March 28, 2025 Original award from which 155 shares were released

Key Terms

Common shares, derivative exercise/conversion, restricted, Form 4, +1 more

5 terms

Common shares financial

"security_title: "Common shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

restricted financial

"Represents shares released from restriction from shares awarded 3/28/2025."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Strategy Officer financial

"officer_title: "Chief Strategy Officer""

A chief strategy officer (CSO) is the senior executive who crafts a company’s long-term plan and decides which markets, products, partnerships, or investments to prioritize—think of them as the company’s navigator plotting the course. Investors pay attention because the CSO shapes where the company will grow, what risks it will take, and how it will deploy resources; strong strategic direction can improve future revenue and value, while poor choices can weigh on returns.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did FENNEC PHARMACEUTICALS INC. (FENC) report for Christiana Marie Cioffi?

FENNEC PHARMACEUTICALS reported that Chief Strategy Officer Christiana Marie Cioffi acquired 155 common shares. The shares were released from restriction tied to stock awarded on March 28, 2025, and are recorded as a derivative exercise/conversion on April 30, 2026.

How many FENNEC PHARMACEUTICALS (FENC) shares does Christiana Cioffi hold after this Form 4 filing?

After the April 30, 2026 transaction, Christiana Cioffi directly holds 24,020 common shares of FENNEC PHARMACEUTICALS. This figure reflects her position following the release of 155 previously restricted shares that were part of an earlier equity award granted on March 28, 2025.

Was Christiana Cioffi’s FENNEC PHARMACEUTICALS (FENC) transaction an open-market stock purchase?

The transaction was not an open-market stock purchase. It is reported as a derivative exercise/conversion with a price per share of $0.0000, representing 155 restricted shares that became unrestricted from an equity award originally granted on March 28, 2025.

What does the footnote in Christiana Cioffi’s FENNEC (FENC) Form 4 transaction explain?

The footnote explains that the 155 shares represent stock released from restriction from shares awarded on March 28, 2025. This clarifies the transaction as vesting of previously granted equity compensation rather than a new market purchase or sale of FENNEC PHARMACEUTICALS common shares.

What role does Christiana Marie Cioffi hold at FENNEC PHARMACEUTICALS (FENC) in this Form 4?

In this Form 4, Christiana Marie Cioffi is identified as the Chief Strategy Officer of FENNEC PHARMACEUTICALS. The reported transaction reflects routine equity compensation activity associated with her executive role, involving 155 common shares that became unrestricted on April 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Christiana Marie

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	04/30/2026		M		155	A	$0	24,020	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Christiana Cioffi	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)